|Bid||0.0000 x 1000|
|Ask||0.0000 x 1200|
|Day's Range||1.9300 - 2.0700|
|52 Week Range||1.0900 - 2.9100|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
This strategic investment from Life Biosciences will have it making an initial investment of $7.5 million into the company researching treatments for Parkinson’s disease. After this initial investment, the company will also be able to raise an additional $21.9 million from Life Biosciences and other investors. The deal will have the company issuing 272 million new fully paid ordinary shares of Prana Biotechnology stock.
-- a biotech company working on therapies for debilitating neurological disease -- saw its shares shoot up some up 50% to $1.92 on Wednesday, Jan. 2, after getting a promised $31.4 million investment. Boston-based Life Biosciences, a private biopharmaceutical company, is seeking the stake in Prana, and will also lend at least two new big-name board members to the Australia-based drug developer. In total, Life Biosciences could own up to 60% of Prana when the deal is completed.
Geoffrey Kempler has been the CEO of Prana Biotechnology Limited (ASX:PBT) since 2005. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
Prana Biotechnology Limited (ASX:PBT), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is PBT Read More...